# Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors

> **NCT05693844** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 15 (estimated)

## Conditions studied

- Advanced or Metastatic Solid Tumors

## Interventions

- **BIOLOGICAL:** Pan-T booster co-expressing MSLN CAR T cell
- **DRUG:** Albumin-bound paclitaxel
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT05693844
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-20
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05693844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05693844, "Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT05693844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*